These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

91 related items for PubMed ID: 1615020

  • 1. [PAF-antagonists with phospholipid structure. 4. Alkylcarbamoylphospholipids with heteroarene and heterocyclase head groups and variation of the P-N-distance; synthesis, characterization and structure-activity relationship].
    Kertscher HP, Schmidt B, Ostermann G.
    Pharmazie; 1992 Mar; 47(3):172-4. PubMed ID: 1615020
    [Abstract] [Full Text] [Related]

  • 2. [PAF-antagonists with phospholipid structure. 3. Phospholipids with heterocyclane head groups and variations of the phosphorus-nitrogen distance; synthesis, characterization and structure-activity relationship].
    Kertscher HP, Ostermann G.
    Pharmazie; 1991 Nov; 46(11):772-4. PubMed ID: 1811226
    [Abstract] [Full Text] [Related]

  • 3. [PAF-antagonists with phospholipid structure. 2. Phospholipids with heteroarene head groups and variations of the phosphorus-nitrogen distance; synthesis, characterization and structure-activity relationships].
    Kertscher HP, Ostermann G.
    Pharmazie; 1991 Oct; 46(10):708-11. PubMed ID: 1803385
    [Abstract] [Full Text] [Related]

  • 4. [PAF-antagonists with a phospholipid structure. 5. Propanediol phospholipids with various substituted pyridinium and quinuclidinium head groups and variations of the phosphorus-nitrogen distance;synthesis, characterization and structure activity relationship].
    Kertscher HP, Schwabe W, Grupe R.
    Pharmazie; 1993 Jan; 48(1):23-6. PubMed ID: 8460172
    [Abstract] [Full Text] [Related]

  • 5. [PAF-antagonists with lipid structure. 6. Alkylpropandiol lipids with acyl- and ether- structures at the C-3 position and heterocyclic head groups; synthesis, characterization and structure-activity relationship].
    Kertscher HP.
    Pharmazie; 1997 Sep; 52(9):672-5. PubMed ID: 9411454
    [Abstract] [Full Text] [Related]

  • 6. [PAF-antagonists with a phospholipid structure. 1. Phospholipids with hetero-arene head groups: synthesis, characterization and determination of the action of structural elements].
    Kertscher HP, Ostermann G, Findeisen M, Limmer S, Gawrisch K.
    Pharmazie; 1991 Aug; 46(8):575-9. PubMed ID: 1798710
    [Abstract] [Full Text] [Related]

  • 7. Structure-activity relationships in platelet-activating factor (PAF antagonists). 6. Synthesis and in vitro antagonistic activities of 2-substituted 5-oxotetrahydrofurans.
    Favre E, Heymans F, Redeuilh C, Batt JP, Massicot F, Blavet N, Braquet P, Godfroid JJ.
    J Lipid Mediat; 1992 Feb; 5(1):23-40. PubMed ID: 1449553
    [Abstract] [Full Text] [Related]

  • 8. Design, synthesis, and structure-activity relationship studies of novel 1-[(1-acyl-4-piperidyl)methyl]-1H-2- methylimidazo[4,5-c]pyridine derivatives as potent, orally active platelet-activating factor antagonists.
    Carceller E, Merlos M, Giral M, Balsa D, García-Rafanell J, Forn J.
    J Med Chem; 1996 Jan 19; 39(2):487-93. PubMed ID: 8558517
    [Abstract] [Full Text] [Related]

  • 9. Biochemical characterization of the interaction of lipid phosphoric acids with human platelets: comparison with platelet activating factor.
    Sugiura T, Tokumura A, Gregory L, Nouchi T, Weintraub ST, Hanahan DJ.
    Arch Biochem Biophys; 1994 Jun 19; 311(2):358-68. PubMed ID: 8203898
    [Abstract] [Full Text] [Related]

  • 10. Effect of specific antagonists on PAF-induced platelet aggregation and release of plasminogen activator.
    Hofmann B, Ostermann G, Hoffmann A, Klöcking HP, Kertscher HP.
    Biomed Biochim Acta; 1988 Jun 19; 47(10-11):S157-60. PubMed ID: 3248103
    [Abstract] [Full Text] [Related]

  • 11. Synthesis and evaluation of antiplatelet activity of trihydroxychalcone derivatives.
    Zhao LM, Jin HS, Sun LP, Piao HR, Quan ZS.
    Bioorg Med Chem Lett; 2005 Nov 15; 15(22):5027-9. PubMed ID: 16169724
    [Abstract] [Full Text] [Related]

  • 12. Structure-activity relationships in platelet-activating factor (PAF). 5. Synthesis and in vitro antagonistic activities of ketophosphonates.
    Furno-de Winter A, Broquet C, Haelters JP, Massicot F, Sturtz G, Godfroid JJ.
    J Lipid Mediat; 1991 Nov 15; 3(3):289-300. PubMed ID: 1773030
    [Abstract] [Full Text] [Related]

  • 13. PAF-agonistic and -antagonistic behaviour of new synthetic ether phospholipids. I. Studies on blood platelets in vitro.
    Ostermann G, Hofmann B, Kertscher HP, Till U.
    J Lipid Mediat; 1990 Nov 15; 2(1):21-31. PubMed ID: 1966804
    [Abstract] [Full Text] [Related]

  • 14. Structure-activity relationships in platelet-activating factor. 12. Synthesis and biological evaluation of platelet-activating factor antagonists with anti-HIV-1 activity.
    Serradji N, Martin M, Bensaid O, Cisternino S, Rousselle C, Dereuddre-Bosquet N, Huet J, Redeuilh C, Lamouri A, Dong CZ, Clayette P, Scherrmann JM, Dormont D, Heymans F.
    J Med Chem; 2004 Dec 02; 47(25):6410-9. PubMed ID: 15566310
    [Abstract] [Full Text] [Related]

  • 15. In vitro platelet-activating factor receptor binding inhibitory activity of pinusolide derivatives: a structure-activity study.
    Han BH, Yang HO, Kang YH, Suh DY, Go HJ, Song WJ, Kim YC, Park MK.
    J Med Chem; 1998 Jul 02; 41(14):2626-30. PubMed ID: 9651167
    [Abstract] [Full Text] [Related]

  • 16. 1,5-Benzodiazepines. X. Dialkylamino substituted 1,5-benzodiazepine and [1,2,4]triazolo [4,3-a][1,5] benzodiazepine derivatives with inhibitory activity on PAF-induced platelet aggregation.
    Di Braccio M, Roma G, Grossi GC, Leoncini G, Maresca M.
    Farmaco; 1992 Jan 02; 47(1):77-90. PubMed ID: 1616579
    [Abstract] [Full Text] [Related]

  • 17. Synthesis and biological evaluation of novel steroid-modified ether phospholipids.
    Karantonis HC, Pitsinos EN, Antonopoulou S, Couladouros EA, Demopoulos CA.
    Chem Phys Lipids; 2005 Dec 02; 138(1-2):12-9. PubMed ID: 16202400
    [Abstract] [Full Text] [Related]

  • 18. A novel class of platelet activating factor (PAF) antagonists. I. Synthesis and structure-activity studies on PAF-sulfonamide isosteres.
    Tsuri T, Haga N, Matsui T, Kamata S, Kakushi H, Uchida K.
    Chem Pharm Bull (Tokyo); 1992 Jan 02; 40(1):75-84. PubMed ID: 1605805
    [Abstract] [Full Text] [Related]

  • 19. Structure-activity relationships for platelet-activating factor (PAF) and analogues reveal differences between PAF receptors on platelets and macrophages.
    Stewart AG, Grigoriadis G.
    J Lipid Mediat; 1991 Nov 02; 4(3):299-308. PubMed ID: 1662547
    [Abstract] [Full Text] [Related]

  • 20. [Effect of analogs and antagonists of the thrombocyte-activating factor (PAF) on blood platelet aggregation].
    Lakin KM, Kulikov VI, Manevich EM, Muliar AG, Shvets VI.
    Farmakol Toksikol; 1988 Nov 02; 51(4):113-23. PubMed ID: 2847936
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.